Close Menu

Breaking News

Filter tips for use with QiaSymphony SP/AS instruments may leak, which could lead to delayed or inaccurate results and cause serious injury or death.

The bipartisan bill aims to provide federal support to children who are ill from an unknown cause and could gain insights into diagnosis or treatment approaches via WGS.

When blood amyloid levels are combined with other risk factors, people with early Alzheimer's brain changes can be identified with high accuracy.

The updated test now includes additional susceptibility testing and clinical interpretive breakpoints that are compliant with 2019 European guidance.

The Cyprus-based company has been offering a cell-free DNA-based noninvasive prenatal test for fetal aneuploidies, called Veracity, since 2015.

The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.

Temple City, California-based Fulgent offers genetic tests for a range of diseases and disorders, as well as custom panels and sequencing services.

Ortho's assay, which aids in quickly and accurately diagnosing heart attacks, runs on its new Vitros XT 7600 Integrated System, among other Ortho systems.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.

They are seeking to determine the concordance between thymidine kinase 1 enzyme concentration in serum and patients' clinical response to treatment.

The combined company will offer laboratory testing and digital technologies for diagnosing and managing lupus, multiple sclerosis, and other autoimmune diseases.

Of the 27 companies in the index, 12 firms' share prices retreated last month, 14 companies' stocks increased, and one firm's share value was flat.

The company also received a contract from the Henry M. Jackson Foundation for a separate sepsis test.

The firms said that their respective technologies are complementary and bridge a technical gap between pathology, radiology, and oncology.

The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.

The diagnostic can now be used to identify patients with esophageal squamous cell carcinoma who may benefit from first-line treatment with Keytruda.

The deals follow a pair of other recent acquisitions by Precision for Medicine in the artificial intelligence technology and biomarker analysis fields.

The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.

The regulatory approval means that the assay for minimal residual disease is available to monitor B cell blood cancers in patients in all 50 states.

The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.

Product and service revenues were up 10 percent year over year to $22.4 million compared to $20.4 million in the year-ago quarter.

The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.

The ruling overturned a lower court decision that blocked ACLA's suit challenging the data collection process used by CMS to set test prices under PAMA.

Pages